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Effects of a novel tyrosine kinase inhibitor in rheumatoid
arthritis synovial fibroblasts
Abstract
OBJECTIVE: Biologicals have revolutionised the treatment of rheumatoid arthritis (RA). However,
progressive joint destruction can still be observed in many patients and the search for novel molecular
therapies targeting specific signalling pathways is ongoing. In the present study, we investigated the
effects of GW282974, a novel compound directed against tyrosine kinase activity with respect to the
potential suppression of inflammation and destruction. METHODS: Synovial tissue specimens were
obtained from RA patients undergoing surgical joint replacement. Rheumatoid arthritis synovial
fibroblasts (RASFs) were stimulated with cytokines and GW282974 was added in different
concentrations. Gene expression was checked by TaqMan PCR, using 18S as housekeeping gene.
Protein analysis was quantified by ELISA. Cell growth and proliferation was measured using the
"ViaLight" proliferation assay. RESULTS: EGF had no effect on the gene expression profile of RASFs
when used as single stimulatory agent. In combination with pro-inflammatory mediators however, EGF
showed a synergistic effect. The expression of matrix metalloproteinases, inflammatory cytokines and
cyclooxygenase-2 on mRNA levels was strongly increased, whereas the addition of GW282974
abrogated these effects in a dose-dependent manner. These data could be confirmed on protein/lipid
levels analysing the supernatants of RASFs by ELISA. Similarly, cell growth and proliferation of
RASFs were inhibited by GW282974 in a dose- and time-dependent manner. By contrast, no cytotoxic
effects were seen within the concentrations used. DISCUSSION: GW282974 appears to interfere with
the inflammatory and the destructive pathways in RASFs and might therefore be used as novel
therapeutic strategy for the treatment of RA.
doi:10.1136/ard.2007.072330 
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Objective: Biologicals have revolutionised the treatment
of rheumatoid arthritis (RA). However, progressive joint
destruction can still be observed in many patients and the
search for novel molecular therapies targeting specific
signalling pathways is ongoing. In the present study, we
investigated the effects of GW282974, a novel compound
directed against tyrosine kinase activity with respect to
the potential suppression of inflammation and destruction.
Methods: Synovial tissue specimens were obtained from
RA patients undergoing surgical joint replacement.
Rheumatoid arthritis synovial fibroblasts (RASFs) were
stimulated with cytokines and GW282974 was added in
different concentrations. Gene expression was checked
by TaqMan PCR, using 18S as housekeeping gene. Protein
analysis was quantified by ELISA. Cell growth and
proliferation was measured using the ‘‘ViaLight’’ prolif-
eration assay.
Results: EGF had no effect on the gene expression profile
of RASFs when used as single stimulatory agent. In
combination with pro-inflammatory mediators however,
EGF showed a synergistic effect. The expression of matrix
metalloproteinases, inflammatory cytokines and cycloox-
ygenase-2 on mRNA levels was strongly increased,
whereas the addition of GW282974 abrogated these
effects in a dose-dependent manner. These data could be
confirmed on protein/lipid levels analysing the super-
natants of RASFs by ELISA. Similarly, cell growth and
proliferation of RASFs were inhibited by GW282974 in a
dose- and time-dependent manner. By contrast, no
cytotoxic effects were seen within the concentrations
used.
Discussion: GW282974 appears to interfere with the
inflammatory and the destructive pathways in RASFs and
might therefore be used as novel therapeutic strategy for
the treatment of RA.
Rheumatoid arthritis (RA) is a chronic inflamma-
tory disorder that is characterised by synovial
hyperplasia, altered immune responses and inflam-
mation. The rheumatoid synovium is distinguished
by the presence of a unique cell type, the RA
synovial fibroblast (RASF), which shows morpho-
logical and molecular features of an activated
phenotype.1 2 These features include the expression
of proto-oncogenes and alterations in the regula-
tion of the cell cycle, leading to the release of pro-
inflammatory mediators and matrix-degrading
enzymes such as matrix metalloproteinases
(MMPs) and cathepsins. These events ultimately
result in the progressive destruction of tendons,
articular cartilage, and bone. Anticytokine thera-
pies and novel biologicals have revolutionised the
therapy of RA. In many patients however,
progressive joint destruction can still be observed
despite the combined use of novel biologicals and
immunosuppressive agents. While the develop-
ment of pharmacologic inhibitors of MMPs has
experienced a major setback due to the carcino-
genicitiy of some compounds,3 intensive searching
for novel substances that might target destruction
and inflammation within the rheumatoid syno-
vium is ongoing. We thus investigated the effects
of GW282974, a quinazoline derivative directed
against tyrosine kinase activity related to epider-
mal growth factor (EGF) receptor.4
EGF is a protein growth factor that has been
detected within the synovial fluid of RA patients in
high concentrations.5 Moreover, EGF was identified
as important factor that stimulates the release of
inflammatory mediators and induces the growth of
synovial cells,6 7 probably by acting in a synergistic
manner with the key pathogenetic mediators of RA.8–
10 EGF-receptor (EFGR, or HER), however, forms a
family of surface receptors with tyrosine kinase
activity including ErbB1 and ErbB2.11 Activation of
EGFR has been linked to various cellular processes
including proliferation, differentiation, and angiogen-
esis.11 In addition, EGFR appears to induce the
expression of cyclooxygenase (COX-)2 in different
tissues, thus leading to the production of bioactive
lipids and potent inflammatory mediators, for
example prostaglandin (PG)E2.
12 In the context of
RA, it was also shown that ErbB2 is highly expressed
on the cell surface of synovial cells7 making it a
potential target for future therapies.
In recent years, specific therapies against the
EGFR family have emerged. Numerous studies
performed in vivo and in vitro have demonstrated
that the interruption of signalling by EGFR
inhibitors directed against the extracellular (mono-
clonal antibodies) or intracellular domain of the
receptor (tyrosine kinase inhibitors) results in
inhibition of cell growth and viability.11 13
Furthermore, a growing body of evidence sug-
gests the presence of a functional crosstalk
between EGFR and COX-2 pathways (reviewed
in Mann et al and Dannenberg et al),14 15 which
would additionally increase the impact of specific
therapeutic interference in the setting of rheuma-
toid arthritis.
In the present study, we addressed this issue by
analysing the expression pattern of several MMPs,
IL-6, cathepsin K and COX-2 in RASFs upon




GW282974 was provided from GlaxoSmithKline
(Stevenage, UK). Epidermal growth factor (EGF),
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tumour necrosis factor a (TNFa) and interleukin (IL-)1a were all
purchased from R&D Systems (Abingdon, Oxfordshire, UK).
Cells/cell culture
Synovial tissue specimens were obtained from RA patients
(n = 5, Clinic of Orthopedic Surgery, Schulthess Hospital
Zurich, Zurich, Switzerland) undergoing surgical joint replace-
ment. All RA patients fulfilled the American College of
Rheumatology (ACR) criteria for RA.16 All tissue analyses were
performed according to the regulations by the ethical committee
Zurich. RASFs were isolated from synovial tissues, digested by
collagenase, and used from passages 4–8 as described pre-
viously.17 RASFs were cultured in Dulbecco’s modified Eagle’s
medium (DMEM, Gibco). DMEM was supplemented with 10%
heat-inactivated foetal calf serum (FCS), 15 mmol/litre HEPES,
2 mmol/litre L-glutamine, 50 mg/ml streptomycin, 100 U of
penicillin, and 2 ml/ml fungizone.
For stimulation, 0.56105 RASF were stimulated with IL-1b
(1 ng/ml), TNFa (10 ng/ml)and/or EGF(1 ng/ml) for 48 h.
Afterwards, the supernatants were collected and RNA was
isolated. The number of cells was determined by the CASY-1
cell counter (Scha¨rfe System, Reutlingen, Germany). GW282974
was added 1 h before incubation with cytokines.
TaqMan reverse transcriptase (RT)-PCR
Total RNA was isolated using an RNeasy kit (Qiagen, Basel,
Switzerland), converted into cDNA, and gene expression was
quantified by RT-PCR as described previously.18 Gene transcript
levels of MMP-1, -3, -13, -14, IL-6, cathepsin K and COX-2, as
well as 18S rRNA were quantified by gene assays (Applied
Biosystems, Foster City, California, USA) using RT-PCR.
Fluorescence activated cell sorting (FACS)
Flow cytometry was performed using a FACScan flow
cytometer (Becton Dickinson, Basel, Switzerland). A minimum
of 16104 cells per sample were acquired in list mode and
analysed using Cell quest software (Becton Dickinson
Immunocytometry System, San Jose, California, USA).
Detection of apoptosis
A total of 0.56105 cells were examined for apoptosis using
Annexin V-PE according to the manufacturer’s protocol. Briefly,
adherent cells were trypsinised, centrifuged at 500 g for 10 min,
and resuspended in 100 ml of FACS binding buffer (BD
Pharmingen, San Diego, California, USA). Annexin V-PE was
added directly to the cells. After incubation for 15 min at room
temperature, the cells were analysed by FACS (FACScalibur,
Becton Dickinson Mansfield, Massachusetts, USA). Treatment
with FasL (100 ng/ml) was used as positive control.
‘‘ViaLight’’ proliferation assay
Cell viability was assessed with the ViaLight HS Kit (Cambrex,
Verviers, Belgium), according to the manufacturer’s protocol. This
assay is based upon the bioluminescent measurement of ATP
levels. Briefly, unstimulated cells were cultivated in 12-well plates
at a density of 4000 cells/well, lysed at defined timepoints, and
ATP was extracted. After addition of the substrate, the generated
luminescence signal was measured in a SIRIUS Luminometer
(Berthold Detection Systems, Pforzheim, Germany).
Immunoassay
Levels of MMP-1 and prostaglandin E2 (PGE2) protein were
determined by quantitative colourimetric sandwich ELISA
(MMP-1: Amersham Biosciences, GE Healthcare UK Limited;
PGE2: R&D Systems) according to the manufacturer’s instruc-
tions. Concentrations were calculated using a standard curve
generated with specific standards provided by the manufac-
turer. IL-6 was measured using a Luminex assay developed ‘‘in
house’’ at GlaxoSmithKline. IL-6 standard was from R&D
Systems.
Statistical analysis
All data are expressed as mean (SD). Statistical analysis was
performed using the GraphPad Prism Software, 4.03 (Graph Pad
Software Inc., San Diego, California, USA). For analysis
between different groups the Mann–Whitney U test was used,
and a value of p,0.05 was considered statistically significant.
RESULTS
Stimulation of RASFs
To determine the ability of RASFs to respond upon stimulation
with epidermal growth factor (EGF) and pro-inflammatory
cytokines such as tumour necrosis factor (TNF)-a and
interleukin (IL)-1b, we first examined the expression levels of
matrix metalloproteinases (MMP)-1, -3, -13, -14, cathepsin K,
IL-6, -8 and COX-2. As shown in fig 1, the combination of EGF
(1 ng/ml), IL-1b (1 ng/ml) and TNFa (10 ng/ml) reached the
highest expression levels of MMP-1 (fig 1A), MMP-3 (fig 1B),
MMP-13 (fig 1C), IL-6 (fig 1D), and COX-2 (fig 1E) when
checked by RT-PCR 24 h after stimulation. Addition of EGF as a
single stimulatory agent revealed only marginal effects at the
dosages used. By contrast, no effect was observed for MMP-14
and cathepsin K (data not shown). Interestingly, EGF alone
showed virtually no stimulation of RASFs in all experimental
settings (data not shown). When used in addition to TNFa and
IL-1b, however, synergistic effects could be seen. In particular,
the mRNA expression levels for MMP-1 were increased by 25
(16)–fold (p = 0.03) when RASFs were stimulated with IL-1b
and TNFa, whereas combined stimulation of EGF with IL-1b
and TNFa increased the mRNA levels of MMP-1 by 42 (4)-fold.
Similarly, mRNA for MMP-3 was elevated by 976 (932) and by
1884 (692)-fold, respectively. MMP-13 was significantly up-
regulated by 39 (17) (p = 0.01) and by 53 (4)-fold under
combined stimulation. IL-6 was increased by 199 (94)
(p = 0.01) and by 247 (125)-fold, respectively. The expression
levels of COX-2 mRNA were increased by 728 (158) (p,0.001)
and by 1070 (35)-fold under additional stimulation by EGF. The
COX-2 gene expression under combined stimulation reached
significance (p = 0.04) when compared to the stimulation with
proinflammatory mediators alone.
These data could be confirmed on protein levels for MMP-1
(fig 2), showing an increase from 2.9 (2.1) to 20 (14) ng/ml upon
combined stimulation.
Inhibitory effects of GW282974
Several studies have demonstrated that interfering with the
EGF-mediated signalling might inhibit the invasiveness of
cancer cells, probably by interfering with EGFR autotranspho-
sphorylation and subsequent PI3K/AKT activation.19 20 Since
PI3K are also involved in the activation of MMPs, we next
analysed the effects of the newly developed compound
GW282974 on the expression levels of MMPs and COX-2 in
stimulated RASFs. As illustrated, GW282974 strongly reduced
the mRNA expression levels of MMP-1 in stimulated synovial
cells in a dose-dependent manner, reaching significance when
applying 10 mM of the compound (p,0.05). Thus, MMP-1 was
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reduced from 42 (18) to 24 (11) for 5 mM and to 16 (4)-fold
when 10 mM of GW282974 were used (fig 1A). Similarly,
MMP-3 was reduced from 1884 (1984) to 861 (666) (5 mM), and
to 722 (692)-fold (10 mM; fig 1B). MMP-13 was reduced from 53
(22) to 28 (7) (5 mM) or to 12 (4)-fold (10 mM, p,0.05; fig 1C).
The mRNA expression levels of IL-6 were reduced from 247
(125) to 161 (84) (5 mM) or to 123 (70)-fold (10 mM, fig 1D) and
COX-2 finally was significantly reduced from 1070 (212) to 408
(70) (5 mM, p,0.05) or to 246 (35)-fold (10 mM, p,0.05),
respectively (fig 1E). On protein levels, GW282974 reduced the
expression of MMP-1 from 20 (14) ng/ml to 15 (11) (5 mM) and
11 (9) ng/ml (10 mM).
On protein levels, GW282974 reduced the expression of
MMP-1 from 20 (14) ng/ml to 15 (11) (5 mM) and 11 (9) ng/ml
(10 mM, fig 2).
Since COX-2 metabolises arachidonic acid into eicosanoids
and inflammatory mediators such as PG, the protein levels of
IL-6 and the level of the biolipid PGE2 were measured in the
supernatants of RASFs (fig 3). GW282974 reduced the levels of
IL-6 from 114 (42) ng/ml to 59 (25) ng/ml, (fig 3A) and PGE2
Figure 1 Effect of epidermal growth
factor (EGF) (in combination with tumour
necrosis factor (TNF)a and interleukin
(IL)-1b) and different concentrations of
GW282974 on matrix metalloproteinase
(MMP)-1 (A), MMP-3 (B), MMP-13 (C),
IL-6 (D), and cyclooxegenase (COX)-2 (E)
in synovial fibroblasts (SF) from patients
with rheumatoid arthritis (RA; n = 3).
mRNA expression levels were determined
by TaqMan reverse transcriptase (RT)-
PCR. Results are expressed as mean
(SD), star indicates significance.
Figure 2 Effect of epidermal growth factor (EGF) (alone or in
combination with tumour necrosis factor (TNF)a and interleukin (IL)-1b)
and different concentrations of GW282974 on matrix metalloproteinase
(MMP)-1 in rheumatoid arthritis synovial fibroblasts (RASFs; n = 3).
Protein expression levels were determined by ELISA. Results are
expressed as mean (SD).
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from 107 (24) ng/ml to 12 (6) ng/ml, (fig 3B). The effects
observed on the protein expression levels of MMP-1 were
strongly dose-dependent. With respect to PGE2 and IL-6, only a
marginal dose-dependent effect was seen. These data suggest
that maximal reduction of COX-2 dependent mediators might
already be achieved by using low micromolecular concentra-
tions of GW282974.
Effects of GW282974 on proliferation and apoptosis
Previous work has demonstrated that the inhibition of EGFR
affects viability of malignant cells21–23 and might inhibit growth
and proliferation of RA synovial cells.7 Figure 4 shows the
effects of GW282974 on the proliferation rate of RASFs (n = 4).
The proliferation rate of RASFs stimulated with IL-1b and
TNFa was arbitrarily set as 100%. Single administration of
GW282974 reduced the rate of proliferating fibroblasts in a
dose-dependent manner. Maximal reduction to 87.4 (20)% was
seen by adding 10 mM of GW282974 as analysed by the ViaLight
proliferation assay after 7 days. These findings are consistent
with data obtained from fibroblasts treated with Herceptin (a
monoclonal antibody against EGFR), which reduced the
proliferation of fibroblasts by about 20% (data not shown).
By contrast, no induction of apoptosis could be detected.
When GW282974 was applied in the highest dose used (10 mM),
no differences in the amount of apoptotic cells could be seen
after 48 h when compared to untreated control cells, indicating
that GW282974 has no cytotoxic effects within effective
concentrations.
DISCUSSION
Specific inhibitors of tyrosine kinase activity have emerged as
molecular-targeted agents for the treatment of various diseases,
including chronic myelogenic leukaemia,24 pulmonary hyperten-
sion,25 and lung cancer.26 Here, we report the results of
experiments, in which we tested an inhibitor of tyrosine kinase
activity (GW282974) in RA. GW282974 is a small-molecule
inhibitor directed against the receptor tyrosine kinase activity of
ErbB2 with a claimed 100-fold selectivity at 50 nM.4 For cell
culture, synovial fibroblasts were used representing key players
in the development and perpetuation of this autoimmune-
related joint disorder.
Following the stimulation with EGF in combination with
TNFa and IL-1b, RASFs expressed matrix degrading enzymes
and pro-inflammatory mediators to a higher extent than after
stimulation with TNFa and IL-1b alone. Consistent with the
findings from other studies,7 27 28 EGF thus enhances the effects
of pro-inflammatory mediators on the expression level of genes
involved in inflammation and joint destruction. This synergistic
effect did not reach statistical significance when compared to
the stimulation achieved by inflammatory mediators alone.
Since EGF was added in a very low concentration, the synergism
observed in the present study might still be of biological
relevance underpinning the potential role of EGF in the
pathogenesis of RA.
With respect to the destruction of articular cartilage, we
found a strong reduction of the expression levels of major
MMPs involved in joint destruction (MMP-1, -3, -13) when we
administered GW282974 to stimulated fibroblasts. Since these
enzymes are pivotal agents in the destruction of articular
cartilage and bone, GW282974 might have joint-protective
properties when administered early in the course of RA.
Moreover, increasing evidence indicate a tight connection
between the EGFR and COX-2 pathways, which form a positive
feedback loop.15 29 Thus, activation of EGFR induced the
transcriptional activation of COX-2, probably through activator
protein (AP)-1 and mitogen-activated protein kinases (MAPK),30
for which binding sites have been identified in the COX-2
promoter region.29 In addition, both transcription factors are
highly involved in the pathogenesis of RA (for reviews see
Huber et al and Ospelt et al).31 32 COX-2, by contrast, increases
the expression of EGFR by PGE2, whose production is
enhanced.15 29 33 34
Our current data are in line with these hypotheses. When
GW282974 was administered to RASFs, the expression levels of
MMPs, ILs, COX-2 and, subsequently, the production of
bioactive lipids and pro-inflammatory mediators such as PGE2
and IL-6 were strongly reduced.
It has been previously reported that EGFR blocking agents
affect cell growth and proliferation.35 We also found such effects
when using GW282974, suggesting that therapeutic use of this
compound might indeed reduce the synovial hypercellularity of
RA. In contrast to other studies however, we found no
alterations in the rate of apoptosis of synovial fibroblasts.
This finding is probably due to the low drug concentrations
used in our studies. Another explanation for the differences in
the rate of apoptosis upon inhibition of by GW282974 might be
the high resistance of RASFs against apoptosis-inducing factors
as it was demonstrated repeatedly.17 36 37
TNFa blocking agents achieved great therapeutical success in
the treatment of inflammatory rheumatologic disorders within
recent years and, thus, were supplemented by various novel
cytokine targets such as anti-IL-6-receptor antibodies as well as
cytokine-independent targets including the use of rituximab
(monoclonal antibodies against CD20) that was originally used
in non-Hodgkin’s lymphomas.38 However, a substantial number
of RA patients under TNF-blocking biologicals shows progres-
sive destruction of joint and bone even when combined with
immunosuppressive drugs. By contrast, the development of
non-selective MMP-blocking agents with potential joint-pro-
tective properties was strongly set back by severe side effects of
the drugs, in particular facilitating the formation of metastasis
in animal models and some humans.3
Figure 3 Effect of GW282974 on
prostaglandin E2 (PGE2) and interleukin
(IL)-6 production in rheumatoid arthritis
synovial fibroblasts (RASFs) stimulated
with IL-b/tumour necrisis factor (TNF)a
(n = 3). Levels of IL-6 (A) and of PGE2 (B)
were determined by Luminex (‘‘in house’’
GlaxoSmithKline assay). Results are
expressed as the average percent
inhibition of protein or lipid released with
the compound (5 mM or 10 mM) as
compared to an untreated control.
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The tyrosine kinase inhibitor GW282974 shows substantial
therapeutic impact on the expression levels of matrix degrading
enzymes and pro-inflammatory mediators alike. GW282974
thus appears to act directly on the two interfaces of inflamma-
tion and destruction. Of interest, EGF used as single stimulatory
agent showed virtually no effect on the gene expression profile
RASFs in the experimental settings of the study presented. This
might be due to the low concentration applied or due to low
protein expression of the respective ErbB receptors in the cells
used. By contrast, GW282974 strongly affected the TNF- and
IL-1-mediated expression of disease-relevant genes such as
matrix-degrading enzymes and pro-inflammatory factors.
Moreover, as shown by the results of the proliferation assay,
GW282974 reduced the rate of cytokine-induced proliferation in
RASFs even in the complete absence of EGF. Based on these
findings, we propose a novel, yet undescribed mechanism of
action of the tyrosine kinase inhibitor GW282974 that is
probably unrelated to EGFR activity.
Whether this mechanism is based on the inhibition of a
functional crosstalk between the common molecular pathways
involving TNFa, IL-1 and EGF or, alternatively, whether it is
due to general off-target activities of the compound used, has to
be investigated by further studies.
Regardless, our data emphasise the potential role of
GW282974 as future therapeutic agent in RA.
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